In one paragraphArticle in Journal of natural products, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Xiangrong TianCollege of Forestry, Northwest A&F University, Yangling, Shaanxi 712100, People's Republic of China.ORCID 0000-0001-9964-3038 Dongdong WangMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0002-7824-2507 Wei JiangMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0003-1067-0406 Heidi R BokeschMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.
Brice A P WilsonMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0001-8988-1964 Barry R O'KeefeMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0003-0772-4856 Kirk R GustafsonMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0001-6821-4943 Funding
Natural Products Discovery and Characterization Through Network CollaborationsZIABC011568 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DU, LIN · 2014 to 2025
$17.2MAssay development and screening for molecular targets and discoveryZIABC011904 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, BRICE · 2019 to 2025
$12.8MCell-free assay technologies for the identification of active compoundsZIABC011471 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OKEEFE, BARRY · 2012 to 2025
$12.4MIsolation of bioactive proteins from natural product extractsZIABC011472 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OKEEFE, BARRY · 2012 to 2025
$7.8MCCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011472Intramural NIH HHS ZIA BC011568NCI NIH HHS HHSN261200800001E
6 · The paper itselfAbstract
Indexed as
AlkaloidsAntineoplastic AgentsNaphthyridinesUrochordataAnimalsMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMolecular StructureAlkaloidsAntineoplastic Agentscaulamidine Bcaulamidine Cisocaulamidine Bisocaulamidine Cisocaulamidine DNaphthyridines
Identifiers
PMID37368408
PMCPMC10732314
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390